136 related articles for article (PubMed ID: 29166452)
41. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
42. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
43. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
Cabrera Martín MN; Pasamontes Pingarrón JA; Carreras Delgado JL; Lapeña Gutiérrez L; Delgado Bolton RC; Bittini Copano A; Pérez Castejón MJ; Fernández Pérez C
Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
[TBL] [Abstract][Full Text] [Related]
44. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma.
Zhai G; Zhang M; Xu H; Zhu C; Li B
J Endocrinol Invest; 2010 Mar; 33(3):151-5. PubMed ID: 19783895
[TBL] [Abstract][Full Text] [Related]
45. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.
Saab G; Driedger AA; Pavlosky W; McDonald T; Wong CY; Yoo J; Urbain JL
Thyroid; 2006 Mar; 16(3):267-72. PubMed ID: 16571089
[TBL] [Abstract][Full Text] [Related]
46. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
[TBL] [Abstract][Full Text] [Related]
47. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
[TBL] [Abstract][Full Text] [Related]
48. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
[TBL] [Abstract][Full Text] [Related]
49. 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.
Iagaru A; Masamed R; Singer PA; Conti PS
Mol Imaging Biol; 2006; 8(5):309-14. PubMed ID: 16758370
[TBL] [Abstract][Full Text] [Related]
50. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
51. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
52. 18F-DOPA and 18F-FDG PET/CT, scintigraphic localization and radioguided surgery of recurrent medullary thyroid cancer: two case reports.
Evangelista L; Farsad M; Piotto A; Pelizzo MR
Curr Radiopharm; 2014; 7(2):133-7. PubMed ID: 25355429
[TBL] [Abstract][Full Text] [Related]
53. Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer.
Ciappuccini R; Aide N; Blanchard D; Rame JP; de Raucourt D; Michels JJ; Babin E; Bardet S
PLoS One; 2016; 11(9):e0162482. PubMed ID: 27598385
[TBL] [Abstract][Full Text] [Related]
54. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
Schreinemakers JM; Vriens MR; Munoz-Perez N; Guerrero MA; Suh I; Rinkes IH; Gosnell J; Shen WT; Clark OH; Duh QY
World J Surg Oncol; 2012 Sep; 10():192. PubMed ID: 22985118
[TBL] [Abstract][Full Text] [Related]
55. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
56. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
[TBL] [Abstract][Full Text] [Related]
58. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
[TBL] [Abstract][Full Text] [Related]
59. Current role of radionuclide imaging in differentiated thyroid cancer.
Wong KT; Choi FP; Lee YY; Ahuja AT
Cancer Imaging; 2008 Sep; 8(1):159-62. PubMed ID: 18818134
[TBL] [Abstract][Full Text] [Related]
60. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
